Are You Currently Taking Actos?
The prescription drug Actos is a drug commonly prescribed to patients that suffer from type 3 diabetes. It has been widely used by doctors across the nation since it was first approved for consumer use by the U.S. Food and Drug Administration (FDA) in 1999.
Use of the diabetes drug Actos has recently been linked to an increased risk of bladder cancer. Actos is typically sold in combination with Metformin as Actoplus Met, Actoplus Met XR and Duetact. Taking any of these medications may increase your chance of developing bladder cancer.
For 70 years, the attorneys at Abraham, Watkins, Nichols, Agosto, Aziz & Stogner have successfully handled a variety of pharmaceutical litigation cases. If you or a loved one has been diagnosed with bladder cancer and took Actos to treat type 2 diabetes, please contact our firm via online or call 713-396-3964 (toll free 800-594-4884) for a free consultation.
FDA Issued Safety Alert for Diabetes Drug Actos
Studies show that higher doses of Actos and longer courses of treatment increase the likelihood of bladder cancer. In June 2011, the FDA issued a statement warning about the possibility of bladder cancer for those taking the diabetes drug Actos. The FDA now requires that the risks uncovered in these studies be disclosed on warnings attached to the drug packaging and included in advertisements.
As of June 2011, two European countries have banned the use of the drug. France ordered it removed from all shelves and Germany told doctors to stop prescribing the drug. Despite these risks, Actos remains available to consumers in the United States and Puerto Rico.